BCM
ITOS

Bridgeway Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Bridgeway Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,300
Closed -$223K – 1211
2025
Q1 		$223K Sell
37,300
-31,772
-46% -$233K 0.01% 903
2024
Q4 		$530K Buy
69,072
+3,305
+5% +$28.4K 0.01% 801
2024
Q3 		$671K Buy
65,767
+3,350
+5% +$51.1K 0.01% 784
2024
Q2 		$926K Buy
62,417
+4,500
+8% +$64.5K 0.02% 711
2024
Q1 		$790K Sell
57,917
-63,313
-52% -$690K 0.02% 807
2023
Q4 		$1.33M Sell
121,230
-55,580
-31% -$551K 0.03% 696
2023
Q3 		$1.94M Buy
176,810
+9,006
+5% +$115K 0.05% 554
2023
Q2 		$2.22M Sell
167,804
-99,141
-37% -$1.41M 0.05% 511
2023
Q1 		$3.63M Buy
266,945
+23,445
+10% +$420K 0.1% 351
2022
Q4 		$4.76M Hold
243,500
– – 0.12% 286
2022
Q3 		$4.64M Buy
243,500
+128,500
+112% +$2.96M 0.12% 295
2022
Q2 		$2.37M Buy
+115,000
New +$2.73M 0.05% 487

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's ITOS Position: Q2 2025 in Review

Bridgeway Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 37,300 shares — an estimated $223K sold.

Bridgeway Capital Management first reported a position in ITOS in Q2 2022 and held it in 12 quarters. The position peaked at $4.76M in Q4 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Bridgeway Capital Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 37,300 iTeos Therapeutics shares in Q2 2025, an estimated $223K.
  • Bridgeway Capital Management first reported a position in iTeos Therapeutics in Q2 2022 and held it in 12 quarters.
  • Bridgeway Capital Management's iTeos Therapeutics position peaked at $4.76M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.